keyword
MENU ▼
Read by QxMD icon Read
search

Pca3

keyword
https://www.readbyqxmd.com/read/28212119/the-role-of-biomarkers-in-undiagnosed-men
#1
Hasan Dani, Stacy Loeb
PURPOSE OF REVIEW: This article intends to review biomarkers derived from blood, urine, and tissue that can aid in the diagnosis of prostate cancer (PCa). RECENT FINDINGS: PCa screening requires tools that complement prostate-specific antigen (PSA) with a higher specificity for clinically significant disease. Novel blood biomarkers, such as the Prostate Health Index (phi) and 4Kscore, utilize isoforms of PSA to more accurately predict high-grade PCa than traditional tools such as PSA and the percentage free-to-total PSA...
February 16, 2017: Current Opinion in Urology
https://www.readbyqxmd.com/read/28187449/low-pca3-expression-is-a-marker-of-poor-differentiation-in-localized-prostate-tumors-exploratory-analysis-from-12-076-patients
#2
Mohammed Alshalalfa, Gerald W Verhaegh, Ewan A Gibb, Maria Santiago-Jiménez, Nicholas Erho, Jennifer Jordan, Kasra Yousefi, Lucia L C Lam, Tyler Kolisnik, Jijumon Chelissery, Roland Seiler, Ashley E Ross, R Jeffrey Karnes, Edward M Schaeffer, Tamara T Lotan, Robert B Den, Stephen J Freedland, Elai Davicioni, Eric A Klein, Jack A Schalken
BACKGROUND: Prostate cancer antigen 3 (PCA3) is a prostate cancer diagnostic biomarker that has been clinically validated. The limitations of the diagnostic role of PCA3 in initial biopsy and the prognostic role are not well established. Here, we elucidate the limitations of tissue PCA3 to predict high grade tumors in initial biopsy. RESULTS: PCA3 has a bimodal distribution in both biopsy and radical prostatectomy (RP) tissues, where low PCA3 expression was significantly associated with high grade disease (p<0...
February 7, 2017: Oncotarget
https://www.readbyqxmd.com/read/28115190/racial-variation-in-the-utility-of-urinary-biomarkers-pca3-and-t2erg-in-a-large-multicenter-study
#3
Padraic G O'Malley, Daniel P Nguyen, Bashir Al Hussein Al Awamlh, Guojiao Wu, Ian M Thompson, Martin Sanda, Mark Rubin, John T Wei, Richard Lee, Paul Christos, Chris Barbieri, Douglas S Scherr
BACKGROUND: It is unknown whether urinary biomarkers for prostate cancer (PCa) have added utility to clinical risk calculators in different racial groups. OBJECTIVE: Examine the added utility to clinical risk calculators for urinary biomarkers in prediction of PCa in African American (AA) and non-AA men. DESIGN: Demographics, Prostate Cancer Prevention Trial (PCPT) risk scores, biomarker data (PCA3 and T2ERG), and biopsy pathology features prospectively collected from 718 men as part of the Early Detection Research Network (EDRN)...
January 20, 2017: Journal of Urology
https://www.readbyqxmd.com/read/28061466/prostate-cancer-proteomics-current-trends-and-future-perspectives-for-biomarker-discovery
#4
Cristiana Pistol Tanase, Elena Codrici, Ionela Daniela Popescu, Simona Mihai, Ana-Maria Enciu, Laura Georgiana Necula, Adrian Preda, Gener Ismail, Radu Albulescu
The clinical and fundamental research in prostate cancer - the most common urological cancer in men - is currently entering the proteomic and genomic era. The focus has switched from one single marker (PSA) to panels of biomarkers (including proteins involved in ribosomal function and heat shock proteins). Novel genetic markers (such as Transmembrane protease serine 2 (TMPRSS2)-ERG fusion gene mRNA) or prostate cancer gene 3 (PCA3) had already entered the clinical practice, raising the question whether subsequent protein changes impact the evolution of the disease and the response to treatment...
January 4, 2017: Oncotarget
https://www.readbyqxmd.com/read/27995111/prostate-cancer-biomarkers-are-we-hitting-the-mark
#5
REVIEW
Shannon McGrath, Daniel Christidis, Marlon Perera, Sung Kyu Hong, Todd Manning, Ian Vela, Nathan Lawrentschuk
PURPOSE: Localised prostate cancer diagnosis and management is increasingly complex due to its heterogeneous progression and prognostic subgroups. Pitfalls in current screening and diagnosis have prompted the search for accurate and invasive molecular and genetic biomarkers for prostate cancer. Such tools may be able to distinguish clinically significant cancers from less aggressive variants to assist with prostate cancer risk stratification and guide decisions and healthcare algorithms...
December 2016: Prostate International
https://www.readbyqxmd.com/read/27925173/potential-of-long-non-coding-rnas-in-cancer-patients-from-biomarkers-to-therapeutic-targets
#6
REVIEW
Subash Chandra Gupta, Yashoda Nandan Tripathi
Because of high specificity and easy detection in the tissues, serum, plasma, urine and saliva, interest in exploring the potential of long non-coding RNAs (lncRNAs) in cancer patients continues to increase. LncRNAs have shown potential as a biomarker in the diagnosis and prognosis of bladder cancer, prostate cancer, gastric cancer, pancreatic cancer, breast cancer and many other cancer types. Some lncRNAs have also been used as adjunct to improve the specificity and sensitivity of existing biomarkers. The molecular tools such as RNA-seq, RNA-FISH, ic-SHAPE and quantitative real-time PCR have been used for examining the lncRNAs' potential...
December 7, 2016: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/27922627/blood-based-and-urinary-prostate-cancer-biomarkers-a-review-and-comparison-of-novel-biomarkers-for-detection-and-treatment-decisions
#7
REVIEW
R J Hendriks, I M van Oort, J A Schalken
BACKGROUND: The diagnosis of prostate cancer (PCa) is currently based on serum PSA testing and/or abnormal digital rectal examination and histopathologic evaluation of prostate biopsies. The main drawback of PSA testing is the lack of specificity for PCa. To improve early detection of PCa more specific biomarkers are needed. In the past few years, many new promising biomarkers have been identified; however, to date, only a few have reached clinical practice. METHODS: In this review, we discuss new blood-based and urinary biomarker models that are promising for usage in PCa detection, follow-up and treatment decision-making...
December 6, 2016: Prostate Cancer and Prostatic Diseases
https://www.readbyqxmd.com/read/27915475/how-precisely-can-prostate-cancer-be-managed
#8
REVIEW
Liyan Zhuang, Matthew T Johnson
Progress has been made in applying genetic information to disease management in the postgenomic era, and precision medicine is emerging in prostate cancer management. The prostate health index, the 4-kallikrein (4K) score, and the PCA3, TMPRSS2- ERG, and Prostarix tests have potential for refining prostate cancer screening in conjunction with traditional prostate-specific antigen testing. The Confirm MDx and PCA3 tests have shown promise in identifying men who need be rebiopsied after a primary negative biopsy...
November 2016: International Neurourology Journal
https://www.readbyqxmd.com/read/27792187/prostate-cancer-detection-and-prognosis-from-prostate-specific-antigen-psa-to-exosomal-biomarkers
#9
REVIEW
Xavier Filella, Laura Foj
Prostate specific antigen (PSA) remains the most used biomarker in the management of early prostate cancer (PCa), in spite of the problems related to false positive results and overdiagnosis. New biomarkers have been proposed in recent years with the aim of increasing specificity and distinguishing aggressive from non-aggressive PCa. The emerging role of the prostate health index and the 4Kscore is reviewed in this article. Both are blood-based tests related to the aggressiveness of the tumor, which provide the risk of suffering PCa and avoiding negative biopsies...
October 26, 2016: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/27775119/novel-metal-free-organic-dyes-possessing-fused-heterocyclic-structural-motifs-for-efficient-molecular-photovoltaics
#10
Ayyanar Karuppasamy, Kesavan Stalindurai, Jia-De Peng, Kuo-Chuan Ho, Chennan Ramalingan
Reported herein are six novel metal free organic dyes such as PCA1-PCA3 and PCTA1-PCTA3 featuring fused heterocyclic structural motifs such as phenothiazine and alkylcarbazole. Photophysical/electrochemical properties and nanocrystalline TiO2 based dye-sensitized solar cell performance of the same have been investigated. Electronic distribution within the molecules has been determined through a computational approach. The overall power conversion efficiencies of the devices with the utilization of dyes PCA1-PCA3 and PCTA1-PCTA3 as sensitizers ranges between 4...
October 24, 2016: Physical Chemistry Chemical Physics: PCCP
https://www.readbyqxmd.com/read/27743381/snail-activated-long-non-coding-rna-pca3-up-regulates-prkd3-expression-by-mir-1261-sponging-thereby-promotes-invasion-and-migration-of-prostate-cancer-cells
#11
Jin-Hua He, Bao-Xia Li, Ze-Ping Han, Mao-Xian Zou, Li Wang, Yu-Bing Lv, Jia-Bin Zhou, Ming-Rong Cao, Yu-Guang Li, Jing-Zhi Zhang
Rapidly accumulated evidence has shown that long non-coding RNA (lncRNAs) disregulation is involved in human tumorigenesis in many cancers, including prostate cancer (PCa). LncRNAs can regulate essential pathways that contribute to tumor initiation and progression with tissue specificity, which suggests that lncRNAs could be valuable biomarkers and therapeutic targets. Prostate cancer antigen 3 (PCA3), also known as differential display code 3 (DD3), is one such lncRNA that maps to chromosome 9q21-22. PCA3 expression is highly specific to PCa...
October 14, 2016: Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine
https://www.readbyqxmd.com/read/27730440/recent-progress-and-perspectives-on-prostate-cancer-biomarkers
#12
REVIEW
Shingo Hatakeyama, Tohru Yoneyama, Yuki Tobisawa, Chikara Ohyama
The application of prostate-specific antigen (PSA) in prostate cancer (PC) screening, diagnosis, and prognosis has improved the clinical management of PC patients. However, the PSA assay has been faced with criticism due to its potential association with over-diagnosis and subsequent overtreatment of patients with indolent disease. The United States Preventive Services Task Force incited much debate over PSA-based screening in 2012 by recommending against this approach. However, the PSA assay remains the first-line tool for the early detection of PC...
October 11, 2016: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/27689066/prostate-based-biofluids-for-the-detection-of-prostate-cancer-a-comparative-study-of-the-diagnostic-performance-of-cell-sourced-rna-biomarkers
#13
Matthew J Roberts, Renee S Richards, Clement W K Chow, Suhail A R Doi, Horst Joachim Schirra, Marion Buck, Hemamali Samaratunga, Joanna Perry-Keene, Diane Payton, John Yaxley, Martin F Lavin, Robert A Gardiner
BACKGROUND: Prostate cancer (PCa) diagnosis requires improvement with the aid of more accurate biomarkers. Postejaculate urethral washings (PEUW) could be a physiological equivalent to urine obtained following rectal prostatic massage, the current basis for the prostate cancer antigen 3 (PCA3) test. The aim of this study was to investigate if PEUW contained prostate-based material, evidenced by the presence of prostate specific antigen (PSA), and to evaluate the diagnostic performance of PEUW-based biomarkers...
September 2016: Prostate International
https://www.readbyqxmd.com/read/27630329/prognostic-significance-of-tmprss2-erg-fusion-gene-in-prostate-cancer
#14
Vlastimil Kulda, Ondrej Topolcan, Radek Kucera, Michaela Kripnerova, Kristyna Srbecka, Milan Hora, Ondrej Hes, Jiri Klecka, Vaclav Babuska, Milena Rousarova, Veronika Benson, Martin Pesta
BACKGROUND/AIM: Current research of prostate cancer (PCa) offers a promising way of identifying patients with adverse prognosis who do benefit from radical treatment that can affect quality of life as resections are associated with numerous side-effects. The aim of our study was to evaluate the relationship of TMPRSS2-ERG fusion gene status, tumor tissue prostate-specific antigen (PSA), prostate cancer antigen 3 (PCA3), miR-23b, miR-26a and miR-221 expression levels in combination with preoperative serum PSA level to the risk of PCa recurrence after radical prostatectomy...
2016: Anticancer Research
https://www.readbyqxmd.com/read/27562202/risk-stratification-by-urinary-prostate-cancer-gene-3-testing-before-magnetic-resonance-imaging-ultrasound-fusion-targeted-prostate-biopsy-among-men-with-no-history-of-biopsy
#15
Michael Fenstermaker, Neil Mendhiratta, Marc A Bjurlin, Xiaosong Meng, Andrew B Rosenkrantz, Richard Huang, Fang-Ming Deng, Ming Zhou, William C Huang, Herbert Lepor, Samir S Taneja
OBJECTIVE: To determine whether a combination of prostate cancer gene 3 (PCA3) and magnetic resonance imaging (MRI) suspicion score (mSS) could further optimize detection of prostate cancer on MRI fusion-targeted biopsy (MRF-TB) among men with no history of biopsy. MATERIALS AND METHODS: We included in this study 187 men presenting to our institution between June 2012 and August 2014 who underwent multiparametric MRI (mpMRI) and PCA3 before MRF-TB. Biopsy results, stratified by biopsy indication and PCA3 score, were recorded...
January 2017: Urology
https://www.readbyqxmd.com/read/27543619/presurgical-biomarker-performance-in-the-detection-of-gleason-upgrading-in-prostate-cancer
#16
Kristina Wittig, Johnathan L Yamzon, David D Smith, Daniel R Jeske, Steven S Smith
BACKGROUND: Gleason Score (GS) upgrading is generally considered a trigger for exit to definitive treatment during active surveillance (AS). Predicting the potential for GS upgrading would be of value in assessing AS eligibility. METHODS: We assessed the performance of biomarkers in presurgical specimens of expressed prostatic secretion (EPS) in this setting. RESULTS: Although EPS volume, total recovered RNA, and RNA expression biomarkers (TMPRSS2: ERG, PCA3, PSA) have been successful in both biopsy outcome prediction, and in the prediction of upstaging in active surveillance eligible patients, they were unable to predict upgrading in patients eligible for active surveillance under National Comprehensive Cancer Network guidelines...
December 2016: Cancer Epidemiology, Biomarkers & Prevention
https://www.readbyqxmd.com/read/27391229/a-positive-real-time-elastography-rte-combined-with-a-prostate-cancer-gene-3-pca3-score-above-35-convey-a-high-probability-of-intermediate-or-high-risk-prostate-cancer-in-patient-admitted-for-primary-prostate-biopsy
#17
Yngve Nygård, Svein A Haukaas, Ole J Halvorsen, Karsten Gravdal, Jannicke Frugård, Lars A Akslen, Christian Beisland
BACKGROUND: The standard of care in patients with suspected prostate cancer (PCa) is systematic prostate biopsies. This approach leads to unnecessary biopsies in patients without PCa and also to the detection of clinical insignificant PCa. Better tools are wanted. We have evaluated the performance of real-time elastography (RTE) combined with prostate cancer gene 3 (PCA3) in an initial biopsy setting with the goal of better identifying patients in need of prostate biopsies. METHODS: 127 patients were included in this study; three were excluded because of not measureable PCA3 score leading to 124 evaluable patients...
July 8, 2016: BMC Urology
https://www.readbyqxmd.com/read/27370230/can-atorvastatin-with-metformin-change-the-natural-history-of-prostate-cancer-as-characterized-by-molecular-metabolomic-imaging-and-pathological-variables-a-randomized-controlled-trial-protocol
#18
Matthew J Roberts, John W Yaxley, Geoffrey D Coughlin, Troy R J Gianduzzo, Rachel C Esler, Nigel T Dunglison, Suzanne K Chambers, Robyn J Medcraft, Clement W K Chow, Horst Joachim Schirra, Renee S Richards, Nicholas Kienzle, Macy Lu, Ian Brereton, Hema Samaratunga, Joanna Perry-Keene, Diane Payton, Chikara Oyama, Suhail A Doi, Martin F Lavin, Robert A Gardiner
BACKGROUND: Atorvastatin and metformin are known energy restricting mimetic agents that act synergistically to produce molecular and metabolic changes in advanced prostate cancer (PCa). This trial seeks to determine whether these drugs favourably alter selected parameters in men with clinically-localized, aggressive PCa. METHODS/DESIGN: This prospective phase II randomized, controlled window trial is recruiting men with clinically significant PCa, confirmed by biopsy following multiparametric MRI and intending to undergo radical prostatectomy...
September 2016: Contemporary Clinical Trials
https://www.readbyqxmd.com/read/27337755/the-role-of-psa-in-detection-and-management-of-prostate-cancer
#19
REVIEW
Roger Kirby
The prostate specific antigen (PSA) test clearly provides the opportunity for clinically relevant prostate cancer to be detected at a stage when treatment options are greater and outcomes may be improved. However, in some patients the PSA test may lead to investigations which can identify clinically insignificant cancers which would not have become evident in a man's lifetime. In addition, a raised PSA may often indicate benign prostatic enlargement, and this may provide an opportunity for treatment of this condition before complications develop...
April 2016: Practitioner
https://www.readbyqxmd.com/read/27320841/prostate-magnetic-resonance-imaging-and-magnetic-resonance-imaging-targeted-biopsy-in-patients-with-a-prior-negative-biopsy-a-consensus-statement-by-aua-and-sar
#20
Andrew B Rosenkrantz, Sadhna Verma, Peter Choyke, Steven C Eberhardt, Scott E Eggener, Krishnanath Gaitonde, Masoom A Haider, Daniel J Margolis, Leonard S Marks, Peter Pinto, Geoffrey A Sonn, Samir S Taneja
PURPOSE: After an initial negative biopsy there is an ongoing need for strategies to improve patient selection for repeat biopsy as well as the diagnostic yield from repeat biopsies. MATERIALS AND METHODS: As a collaborative initiative of the AUA (American Urological Association) and SAR (Society of Abdominal Radiology) Prostate Cancer Disease Focused Panel, an expert panel of urologists and radiologists conducted a literature review and formed consensus statements regarding the role of prostate magnetic resonance imaging and magnetic resonance imaging targeted biopsy in patients with a negative biopsy, which are summarized in this review...
June 16, 2016: Journal of Urology
keyword
keyword
17649
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"